PMID- 7524292
OWN - NLM
STAT- MEDLINE
DCOM- 19941104
LR  - 20171116
IS  - 0018-1994 (Print)
IS  - 0018-1994 (Linking)
VI  - 40
IP  - 8
DP  - 1994 Aug
TI  - [Clinical study of TZP-4238 on patients with benign prostatic hypertrophy--with 
      special reference to urodynamics].
PG  - 761-9
AB  - Twenty four cases of benign hypertrophy with bladder outlet obstruction were 
      treated with 17 alpha-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione 
      (TZP-4238), and the effects on urodynamic parameters, clinical efficacy, safety, 
      and usefulness were evaluated. Improvement rate of subjective rate of subjective 
      symptoms was 52.9%. Obstructive symptoms improved more prominently than 
      irritation symptoms. A significant improvement in flow rate of nomograms for 
      maximum flow rate (MFR) and average flow rate (AFR) accompanied with the decrease 
      in the prostatic weight were observed. However, no changes were observed on the 
      urethral sphincter electromyography and the urethral pressure profile. A 
      significant decrease of maximum cystometric capacity was observed, although the 
      effective cystometric capacity was not changed. The overall improvement rate for 
      urodynamic parameters was 43.7%. A significant decrease in weight and diameter of 
      the prostate was observed. The prostatic weight decreased in 57.1%, and the 
      average reduction rate was 15.4%. The overall improvement rate concerning 
      clinical efficacy evaluating both subjective symptoms and objective parameters 
      was 58.8%. Adverse reactions were observed in 5 cases. They were judged as not 
      clinically problematic. Taking into account clinical safety and clinical 
      efficacy, the clinical usefulness was 50.0%. TZP-4238 was considered to be an 
      appropriate agent for treating patients with benign prostatic hypertrophy with 
      bladder outlet obstruction.
FAU - Park, Y C
AU  - Park YC
AD  - Department of Urology, School of Medicine, Kinki University.
FAU - Akiyama, T
AU  - Akiyama T
FAU - Kurita, T
AU  - Kurita T
FAU - Kaneko, S
AU  - Kaneko S
FAU - Mizunaga, M
AU  - Mizunaga M
FAU - Yachiku, S
AU  - Yachiku S
LA  - jpn
PT  - Clinical Trial
PT  - Journal Article
PL  - Japan
TA  - Hinyokika Kiyo
JT  - Hinyokika kiyo. Acta urologica Japonica
JID - 0421145
RN  - 0 (Androgen Antagonists)
RN  - 0SY050L61N (Chlormadinone Acetate)
RN  - FR26FSV5EZ (osaterone acetate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/*pharmacology/*therapeutic use
MH  - Chlormadinone Acetate/*analogs & derivatives/pharmacology/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/*drug therapy
MH  - Urinary Bladder Neck Obstruction/drug therapy
MH  - Urodynamics/*drug effects
EDAT- 1994/08/01 00:00
MHDA- 1994/08/01 00:01
CRDT- 1994/08/01 00:00
PHST- 1994/08/01 00:00 [pubmed]
PHST- 1994/08/01 00:01 [medline]
PHST- 1994/08/01 00:00 [entrez]
PST - ppublish
SO  - Hinyokika Kiyo. 1994 Aug;40(8):761-9.